Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Dr. Jill  Weimer Ph.D.

Chief Science Officer

Mr. Patrik S. Florencio Esq.

Global Chief Compliance & Risk Officer

Dr. Jeffrey P. Castelli Ph.D.

Chief Development Officer

Ms. Diana  Moore

Head of Global Corporate Communications

Ms. Ellen S. Rosenberg

Chief Legal Officer & Corporate Secretary

Mr. Simon Nicolas Reade Harford

Chief Financial Officer

Mr. David M. Clark

Chief People Officer

Andrew  Faughnan

Senior Director of Investor Relations

Ms. Samantha  Prout

Chief Accounting Officer & Controller

Mr. Bradley L. Campbell M.B.A.

Chief Executive Officer, President & Director

Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. Estrutura de gestão

Informação de gestão